Security key
37611X100
RECURSION PHARMACEUTICALS INC - COMMON STOCK (DNA)
CUSIP: 37611X100
Q1 2025 13F Holders as of 31 Mar 2025
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 606,634
- Total 13F value
- $203,000
- Share change
- +606,634
- SEC-reported price per share
- $0.33
- Number of holders
- 1
- Value change
- +$203,000
- Number of buys
- 1
- Shares outstanding
- 518,011,600
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2025
Institutions
1
Top holders
1
DNA full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
RECURSION PHARMACEUTICALS, INC. SEC filings
RECURSION PHARMACEUTICALS, INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 37611X100
Recent filing periods:
Ownership snapshot
Top reported holders of DNA - RECURSION PHARMACEUTICALS INC - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BAILLIE GIFFORD & CO
Disclosed value leader
VANGUARD GROUP INC
Comparable rows
2/15
Latest evidence
31 Dec 2024
13F
13D/G
3/4/5
Lead comparable stake: 6.5%
13 rows are not safely comparable across share classes.
13D/G row: BAILLIE GIFFORD & CO
Showing 1-6 of 15 holder rows.
Quick read
BAILLIE GIFFORD & CO leads the comparable SEC ownership view at 6.5%.
2 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BAILLIE GIFFORD & CO's linked filing trail.
Comparable ownership
Top 2
BAILLIE GIFFORD & CO
6.5%
RA CAPITAL MANAGEMENT, L.P.
2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BAILLIE GIFFORD & CO |
13F
13D/G
Company
|
6.5%
Reported 13D/G
· 31 Dec 2024
|
$168,081,032
24,864,058 shares
|
— | 31 Dec 2024 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
13D/G
Company
|
2%
Reported 13D/G
· 31 Dec 2024
|
$52,221,649
7,725,096 shares
|
— | 31 Dec 2024 |
| Lux Ventures IV, L.P. |
3/4/5
Former 10% Owner
|
—
denominator unverified
|
$137,710,376
13,021,519 shares
|
— | 07 Dec 2021 |
| Mubadala Investment Co PJSC |
3/4/5
13F
10%+ Owner · Company
|
—
denominator unverified
|
$137,333,970
12,985,927 shares
|
— | 02 Mar 2023 |
| Zachary Bogue |
3/4/5
Director, 10%+ Owner
|
—
denominator unverified
|
$39,514,048
3,736,341 shares
|
— | 03 Jul 2023 |
| MIC Capital Partners (Public) Parallel Cayman, LP |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$14,688,335
1,388,889 shares
|
— | 01 Nov 2021 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
1
Shares
606,634
Rows available
1
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2025 vs Q1 2025 Across Filers
Q1 2025 holders
1
Q1 2025 holders
1
Holder diff
0
| Investor | Q1 2025 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q1 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend